Abstract
Abnormalities of lipoprotein metabolism are frequently found in patient with primary gout. The most common lipid abnormality is hypertriglyceridaemia, independent of, and not secondary to, either obesity, alcohol consumption, or carbohydrate intolerance (1,2). On the other hand, it has been emphasized that endogenous hypertriglyceridaemia is a common metabolic disorder associated with an increased risk of coronary heart-disease (3,4). Thus, therapeutic efforts in this field seem to be indicated. However, the dietary and drug treatment is frequently unsatisfactory, as many patients do not respond adequately or manifest untoward side-effects. Recently, clinical trials of chenodeoxycholic acid (C.D.C.A.), a gall-stone dissolving agent, have demonstrated a decrease in serum triglycerides in patients with varying degrees of hypertriglyceridaemia (5,6,7).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
